WO2002088721A3 - Biopolymer marker having a molecular weight of 1206 daltons - Google Patents

Biopolymer marker having a molecular weight of 1206 daltons Download PDF

Info

Publication number
WO2002088721A3
WO2002088721A3 PCT/CA2002/000609 CA0200609W WO02088721A3 WO 2002088721 A3 WO2002088721 A3 WO 2002088721A3 CA 0200609 W CA0200609 W CA 0200609W WO 02088721 A3 WO02088721 A3 WO 02088721A3
Authority
WO
WIPO (PCT)
Prior art keywords
daltons
molecular weight
absence
ability
biopolymer marker
Prior art date
Application number
PCT/CA2002/000609
Other languages
French (fr)
Other versions
WO2002088721A2 (en
Inventor
George Jackowski
Brad Thatcher
Tammy Vrees
Jason Yantha
John Marshall
Original Assignee
Syn X Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn X Pharma Inc filed Critical Syn X Pharma Inc
Priority to AU2002257402A priority Critical patent/AU2002257402A1/en
Publication of WO2002088721A2 publication Critical patent/WO2002088721A2/en
Publication of WO2002088721A3 publication Critical patent/WO2002088721A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Abstract

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or absence of said biopolymer.
PCT/CA2002/000609 2001-04-30 2002-04-26 Biopolymer marker having a molecular weight of 1206 daltons WO2002088721A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002257402A AU2002257402A1 (en) 2001-04-30 2002-04-26 Biopolymer marker having a molecular weight of 1206 daltons

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/845,725 US6627608B2 (en) 2001-04-30 2001-04-30 Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons
US09/845,725 2001-04-30

Publications (2)

Publication Number Publication Date
WO2002088721A2 WO2002088721A2 (en) 2002-11-07
WO2002088721A3 true WO2002088721A3 (en) 2002-12-27

Family

ID=25295944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000609 WO2002088721A2 (en) 2001-04-30 2002-04-26 Biopolymer marker having a molecular weight of 1206 daltons

Country Status (3)

Country Link
US (1) US6627608B2 (en)
AU (1) AU2002257402A1 (en)
WO (1) WO2002088721A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008800B2 (en) * 2001-04-30 2006-03-07 Artemis Proteomics, Ltd. Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons
US20040236603A1 (en) * 2003-05-22 2004-11-25 Biospect, Inc. System of analyzing complex mixtures of biological and other fluids to identify biological state information
US7425700B2 (en) * 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
US20050244973A1 (en) * 2004-04-29 2005-11-03 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
US20120001065A1 (en) * 2009-03-18 2012-01-05 Mayo Foundation for Medical Education and Rsearch Evaluating renal function
CN117233413A (en) 2019-08-05 2023-12-15 禧尔公司 Systems and methods for sample preparation, data generation, and protein crown analysis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538897A (en) * 1994-03-14 1996-07-23 University Of Washington Use of mass spectrometry fragmentation patterns of peptides to identify amino acid sequences in databases
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
WO2000009562A1 (en) * 1998-08-12 2000-02-24 The New York Blood Center, Inc. Novel cleaved fragments of fibrinogen
WO2000049410A2 (en) * 1999-02-16 2000-08-24 The Government Of The United States Of America, As Represented By The Secretary Department Of Health & Human Services, The National Institutes Of Health Lcm (laser capture microdissection) for cellular protein analysis
WO2001005422A2 (en) * 1999-07-15 2001-01-25 Biomerieux Stelhys Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease
WO2001075454A2 (en) * 2000-04-03 2001-10-11 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3809504C1 (en) 1988-03-22 1989-09-21 Bruker - Franzen Analytik Gmbh, 2800 Bremen, De
EP0434792A4 (en) 1989-05-19 1992-05-20 John B. Fenn Multiply charged ions and a method for determining the molecular weight of large molecules
US6020208A (en) 1994-05-27 2000-02-01 Baylor College Of Medicine Systems for surface-enhanced affinity capture for desorption and detection of analytes
US5914238A (en) * 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
DE59709517D1 (en) 1996-08-13 2003-04-17 Biovision Ag METHOD FOR DETECTING THE STATUS OF AN ORGANISM BY MEASURING PEPTIDES
US6207370B1 (en) * 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538897A (en) * 1994-03-14 1996-07-23 University Of Washington Use of mass spectrometry fragmentation patterns of peptides to identify amino acid sequences in databases
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
WO2000009562A1 (en) * 1998-08-12 2000-02-24 The New York Blood Center, Inc. Novel cleaved fragments of fibrinogen
WO2000049410A2 (en) * 1999-02-16 2000-08-24 The Government Of The United States Of America, As Represented By The Secretary Department Of Health & Human Services, The National Institutes Of Health Lcm (laser capture microdissection) for cellular protein analysis
WO2001005422A2 (en) * 1999-07-15 2001-01-25 Biomerieux Stelhys Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease
WO2001075454A2 (en) * 2000-04-03 2001-10-11 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SOBEL JOAN H ET AL: "Antipeptide monoclonal antibodies to defined fibrinogen Aalpha chain regions: Anti-Aalpha 487-498, a structural probe for fibrinogenolysis.", BLOOD, vol. 91, no. 5, 1 March 1998 (1998-03-01), pages 1590 - 1598, XP002211973, ISSN: 0006-4971 *
VAZIRI N D ET AL: "FACTOR XIII AND ITS SUBSTRATES FIBRONECTIN FIBRINOGEN AND ALPHA-2 ANTIPLASMIN IN PLASMA AND URINE OF PATIENTS WITH NEPHROSIS", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, vol. 117, no. 2, 1991, pages 152 - 156, XP008007679, ISSN: 0022-2143 *
WILNER, GEORGE D. ET AL: "Immunochemical studies of human fibrinopeptide A using synthetic peptide homologues", BIOCHEMISTRY (1976), 15(6), 1209-13, 1976, XP002212292 *

Also Published As

Publication number Publication date
WO2002088721A2 (en) 2002-11-07
US20020161185A1 (en) 2002-10-31
US6627608B2 (en) 2003-09-30
AU2002257402A1 (en) 2002-11-11

Similar Documents

Publication Publication Date Title
WO2002088722A3 (en) Biopolymer marker having a molecular weight of 1350 daltons
WO2002088742A3 (en) Biopolymer marker having a molecular weight of 2937 daltons
WO2002088726A3 (en) Biopolymer marker having a molecular weight of 1449 daltons
WO2002088743A3 (en) Biopolymer marker having a molecular weight of 1097 daltons
WO2002088174A3 (en) Biopolymer marker having a molecular weight of 1865 daltons
WO2003046572A3 (en) Biopolymer markers predictive of alzheimers disease
WO2002088715A3 (en) Biopolymer marker having a molecular weight of 1465 daltons
WO2002088711A3 (en) Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
WO2002088719A3 (en) Biopolymer marker having a molecular weight of 1424 daltons
WO2002088747A3 (en) Biopolymer marker having a molecular weight of 1845 daltons
WO2002088724A3 (en) Biopolymer marker having a molecular weight of 1896 daltons
WO2002088745A3 (en) Biopolymer marker having a molecular weight of 2267 daltons
WO2002088727A3 (en) Biopolymer marker having a molecular weight of 1690 daltons
WO2002088721A3 (en) Biopolymer marker having a molecular weight of 1206 daltons
WO2002088712A3 (en) Biopolymer marker state having a molecular weight of 1777 daltons
WO2002088728A3 (en) Biopolymer marker having a molecular weight of 1020 daltons
WO2002088731A3 (en) Biopolymer marker having a molecular weight of 1211 daltons
WO2002088720A3 (en) Biopolymer marker having a molecular weight of 1348 daltons
WO2002088729A3 (en) Biopolymer marker having a molecular weight of 1562 daltons
WO2002088725A3 (en) Biopolymer marker having a molecular weight of 1793 daltons
WO2002088730A8 (en) Biopolymer marker having a molecular weight of 1525 daltons
WO2002088707A3 (en) Biopolymer marker having a molecular weight of 1998 daltons
WO2003046001A3 (en) Protein biopolymer markers predictive of insulin resistance
WO2003046573A3 (en) Protein biopolymer markers predictive of insulin resistance
WO2002088718A3 (en) Biopolymer marker having a molecular weight of 1536 daltons

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP